On Tuesday local time, Neuralink, a brain computer interface startup co founded by Elon Musk, announced that it has obtained approval from an independent review committee to conduct its first human trial of implanting devices into the brains of paralyzed patients.

In a blog article, the company stated: "During the research process, the surgical robot R1 will be used to implant ultra-fine flexible wires of the implantable brain interface device N1 into the brain area that controls motor intention. Once implanted, the N1 implant is invisible in aesthetics, aiming to record brain signals and wirelessly transmit them to the application that decodes motor intention

The company added that this study aims to test the safety and effectiveness of the Neuralink wireless fully implantable brain computer interface, enabling paralyzed patients to control external devices with their brains.

At the same time, the company has officially opened the recruitment of clinical trial patients, and patients paralyzed due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS) may be eligible to participate in this trial.

The company did not disclose when the study would begin. According to Neuralink, the human trial lasted for six years, and participants would first participate in an 18 month study. Afterwards, they would spend at least two hours a week researching brain computer interfaces.

It is worth mentioning that in May this year, Neuralink stated that its first human clinical trial was approved by the US Food and Drug Administration (FDA), which is a key milestone for the field of brain computer interfaces and Neuralink. According to McKinsey's previous prediction, the global brain computer interface industry will generate an economic value of $70 billion to $200 billion over the next 10 to 20 years.

Last month, Neuralink disclosed that it had raised $280 million.